HOUSE 1839116th CongressBecame Public Law No: 116-16.

Medicaid Services Investment and Accountability Act of 2019

Last Action: 4/18/2019

Actions

2019-04-18Became Public Law No: 116-16.
2019-04-18Became Public Law No: 116-16.
2019-04-18Signed by President.
2019-04-18Signed by President.
2019-04-10Presented to President.
2019-04-10Presented to President.
2019-04-10Sponsor introductory remarks on measure. (CR H3224)
2019-04-03Message on Senate action sent to the House.
2019-04-02Passed Senate without amendment by Voice Vote. (consideration: CR S2203)
2019-04-02Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.(consideration: CR S2203)
2019-03-26Received in the Senate, read twice.
2019-03-25Motion to reconsider laid on the table Agreed to without objection.
2019-03-25On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2773-2776)
2019-03-25Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2773-2776)
2019-03-25Considered as unfinished business. (consideration: CR H2781)

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2019-04-18 (49)

Medicaid Services Investment and Accountability Act of 2019

This bill alters several Medicaid programs and funding provisions.

(Sec. 2) The bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services.

(Sec. 3) The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate.

(Sec. 4) The bill also temporarily extends the Medicaid demonstration program for certified community behavioral health clinics.

(Sec. 5) The bill increases funding available to the Money Follows the Person Rebalancing Demonstration Program. (Under this program, the Centers for Medicare & Medicaid Services may award grants to state Medicaid programs to assist states in increasing the use of home and community care for long-term care and decreasing the use of institutional care.)

(Sec. 6) Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

Cosponsors (8)

Kurt Schrader (D-OR)
Markwayne Mullin (R-OK)
FRED UPTON (R-MI)
Debbie Dingell (D-MI)
Brett Guthrie (R-KY)
Kathy Castor (D-FL)
Gus Bilirakis (R-FL)
Van Taylor (R-TX)

Subjects

Birth defects
Blood and blood diseases
Business records
Cardiovascular and respiratory health
Child health
Civil actions and liability
Disability and paralysis
Emergency medical services and trauma care
Family services
HIV/AIDS
Health care costs and insurance
Health care coverage and access
Health care quality
Health personnel
Health programs administration and funding
Health promotion and preventive care
Health technology, devices, supplies
Hereditary and development disorders
Home and outpatient care

Became law: Pub. L. 116-16

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.